Table 3.
Comparison between COVID-19 patients with and without evidence of fibrosis. Non-fibrotic group (n =109); fibrotic group (n =101)
| The studied group, N = 210 | Test | p value | ||
|---|---|---|---|---|
| Non fibrotic, N = 109 | Fibrotic, N = 101 | |||
| Age (years) | ||||
| Mean ±SD | 49.26±13.36 | 58.81±14.82 |
t test 4.91 |
<0.001 |
| Range | 18–76 | 24–94 | ||
| Sex | ||||
| Male | 76 (69.7%) | 73 (72.3%) |
X2 0.17 |
0.65 |
| Female | 33 (30.3%) | 28 (27.7%) | ||
| Severity score | ||||
| Mean ±SD | 7.55±3.32 | 15.20±3.34 |
U 11.09 |
<0.001 |
| Range | 1–14 | 9–20 | ||
| Consolidation/crazy-paving score | ||||
| Mean ±SD | 5.42±3.55 | 12.63±4.22 |
U 10.06 |
<0.001 |
| Range | 0–15 | 5–20 | ||
| Lymphopenia | 64 (58.7%) | 79 (78.2%) |
X2 9.2 |
0.002 |
| Elevated high-sensitivity troponin | 17 (15.6%) | 28 (27.7%) |
X2 4.6 |
0.03 |
| High ferritin levels | 62 (56.9%) | 81 (80.2%) |
X2 13.1 |
<0.001 |
| Elevated CRP | 90 (82.6%) | 95 (94.1%) |
X2 6.6 |
0.01 |
| Elevated d-dimer | 87 (79.8%) | 96 (95.0%) |
X2 10.9 |
0.001 |
| Length of hospital stay | ||||
| Mean ±SD | 8.56±7.03 | 23.26±20.89 |
U 8.26 |
<0.001 |
| Range | 1–37 | 2–170 | ||
| ICU admission | ||||
| No | 102 (93.6%) | 56 (55.4%) |
X2 40.9 |
<0.001 |
| Yes | 7 (6.4%) | 45 (44.6%) | ||
| Steroid | ||||
| No | 27 (24.8%) | 7 (6.9%) |
X2 12.3 |
<0.001 |
| Yes | 82 (75.2%) | 94 (93.1%) | ||